Text Size

Sub Total : $0.00
Place your mouse over each cart item to see full description.

Chemical Name: Ofloxacin

Please select Dosage and Quantity
  Product Manufacturer Country Dosage Quantity Price($USD)    
Ofloxacin  Generic Canada 200 mg 100 $207.99
Ofloxacin  Generic Canada 300 mg 100 $217.99
Ofloxacin  Generic Canada 400 mg 100 $227.99

Floxin Information:

Floxin (Ofloxacin) is a synthetic 4-fluoroquinolone antibacterial agent with bactericidal activity against a wide range of Gram-negative and Gram-positive organisms. It is indicated for the treatment of the following infections when caused by sensitive organisms: Upper and lower urinary tract infections; lower respiratory tract infections; uncomplicated urethral and cervical gonorrhoea; non-gonococcal urethritis and cervicitis, skin and soft tissue infections. General dosage recommendations: The dose of ofloxacin is determined by the type and severity of the infection. The dosage range for adults is 200mg to 800mg daily. Up to 400mg may be given as a single dose, preferably in the morning. Larger doses should be given as two divided doses. Generally, individual doses are to be given at approximately equal intervals. Tarivid tablets should be swallowed with liquid; they should not be taken within two hours of magnesium/aluminium containing antacids, sucralfate or iron preparations since reduction of absorption of ofloxacin can occur. Lower urinary tract infection: 200-400mg daily. Upper urinary tract infection: 200-400mg daily increasing, if necessary, to 400 mg twice a day. Lower respiratory tract infection: 400 mg daily increasing, if necessary, to 400 mg twice daily. Uncomplicated urethral and cervical gonorrhoea: A single dose of 400 mg. Non-gonococcal urethritis and cervicitis: 400 mg daily in single or divided doses. Skin and soft tissue infections: 400 mg twice daily. Impaired renal function: Following a normal initial dose, dosage should be reduced in patients with impairment of renal function. When creatinine clearance is 20-50 ml/minute (serum creatinine1.5-5.0mg/dl) the dosage should be reduced by half (100-200mg daily). If creatinine clearance is less than 20 ml/minute (serum creatinine greater than 5 mg/dl) 100 mg should be given every 24 hours. In patients undergoing haemodialysis or peritoneal dialysis, 100 mg should be given every 24 hours. Impaired liver function: The excretion of ofloxacin may be reduced in patients with severe hepatic dysfunction. Elderly: No adjustment of dosage is required in the elderly, other than that imposed by consideration of renal or hepatic function. Children: Ofloxacin is not indicated for use in children or growing adolescents. Duration of treatment: Duration of treatment is dependent on the severity of the infection and the response to treatment. The usual treatment period is 5-10 days except in uncomplicated gonorrhoea, where a single dose is recommended. Treatment should not exceed 2 months duration. Co-administered magnesium/aluminium antacids, sucralfate or iron preparations can reduce absorption. Therefore, ofloxacin should be taken 2 hours before such preparations. Prolongation of bleeding time has been reported during concomitant administration of Tarivid and anticoagulants. There may be a further lowering of the cerebral seizure threshold when quinolones are given concurrently with other drugs which lower the seizure threshold e.g. theophylline. However, ofloxacin is not thought to cause a pharmacokinetic interaction with theophylline, unlike some other fluoroquinolones. Further lowering of the cerebral seizure threshold may also occur with certain nonsteroidal anti-inflammatory drugs. Ofloxacin may cause a slight increase in serum concentrations of glibenclamide administered concurrently; patients treated with this combination should be closely monitored. With high doses of quinolones, impairment of excretion and an increase in serum levels may occur when co-administered with other drugs that undergo renal tubular secretion (e.g. probenecid, cimetidine, frusemide and methotrexate). Interactions with laboratory tests: Determination of opiates or porphyrins in urine may give false-positive results during treatment with ofloxacin.

Floxin Side Effects:

The overall frequency of adverse reactions from the clinical trial data base is about 7%. The commonest events involved the gastrointestinal system (about 5.0%) and the nervous system (about 2.0%). The following provides a tabulation based on post marketing experience where occasional represents a frequency of 0.1-1.0%, rare <0.1%, very rare <0.01% and isolated cases <<0.01%. Digestive and liver side effects: Occasional: Nausea and vomiting, diarrhoea, abdominal pain, gastric symptoms. (Diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic). Rare: Loss of appetite, increase in liver enzymes and/or bilirubin. Very rare: cholestatic jaundice, hepatitis or severe liver damage may develop. A particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to Clostridium difficile). Even if Clostridium difficile is only suspected, administration of ofloxacin should be discontinued immediately, and appropriate treatment given. Drugs that inhibit peristalsis should not be administered in such cases. Central nervous system: Occasional: Headache, dizziness, sleep disorders, restlessness. Rare: Confusion, nightmares, anxiety, depression, hallucinations and psychotic reactions, drowsiness, unsteady gait and tremor (due to disorders of muscular co-ordination), neuropathy, numbness and paraesthesia or hypaesthesiae, visual disturbances, disturbances of taste and smell (including, in exceptional cases, loss of function), extrapyramidal symptoms. Very rare: Convulsions, hearing disorders (including, in exceptional cases, loss of hearing). These reactions have occurred in some patients after the first dose of ofloxacin. In such cases, discontinue treatment immediately. Cardiovascular system: Tachycardia and a temporary decrease in blood pressure have been reported. Rare: circulatory collapse (due to pronounced drop in blood pressure). Haematological side effects: Very rare: anaemia, leucopenia (including agranulocytosis), thrombocytopenia, pancytopenia. Only in some cases are these due to bone marrow depression. In very rare cases, haemolytic anaemia may develop. Renal side effects: Rare: Disturbances of kidney function. Isolated cases: Acute interstitial nephritis, or an increase in serum creatinine, which may progress to acute renal failure. Allergic and skin side effects: Occasional: Skin rash, itching. Very rare: Rash on exposure to strong sunlight, other severe skin reactions. Hypersensitivity reactions, immediate or delayed, usually involving the skin (e.g. erythema multiforme, Stevens-Johnson syndrome, Lyell's syndrome and vasculitis) may occur. In exceptional circumstances, vasculitis can lead to skin lesions including necrosis and may also involve internal organs. There are rarely other signs of anaphylaxis such as tachycardia, fever, dyspnoea, shock, angioneurotic oedema, vasculitic reactions, eosinophilia. In these cases treatment should be discontinued immediately and where appropriate, supportive treatment given. Isolated cases: Pneumonitis. Other side effects: Rare: Malaise. Very rare: Excessive rise or fall in blood-sugar levels. Weakness, joint and muscle pains (in isolated cases these may be symptoms of rhabdomyolysis). Isolated cases: Tendon discomfort, including inflammation and rupture of tendons (e.g. the Achilles tendon) particularly in patients treated concurrently with corticosteroids. In the event of signs of inflammation of a tendon, treatment with Tarivid must be halted immediately and appropriate treatment must be initiated for the affected tendon. The possibility cannot be ruled out that ofloxacin may trigger an attack of porphyria in predisposed patients. Except in very rare instances (e.g. isolated cases of smell, taste and hearing disorders) the adverse effects observed subsided after discontinuation of ofloxacin.

Ofloxacin should not be used in patients with known hypersensitivity to 4-quinolone antibacterials, or any of the tablet excipients. Ofloxacin should not be used in patients with a past history of tendinitis. Ofloxacin, like other 4-quinolones, is contra-indicated in patients with a history of epilepsy or with a lowered seizure threshold. Ofloxacin is contra-indicated in children or growing adolescents, and in pregnant or breast-feeding women, since animal experiments do not entirely exclude the risk of damage to the cartilage of joints in the growing subject. Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents.

The generic alternative is not manufactured by the company that makes the brand product.

All prices are in US dollars.

The content on this page has been supplied to MediSave.ca by an independent third party contracted to provide information for our website. MediSave.ca relies on these third parties to create and maintain this information and cannot guarantee the medical efficacy, accuracy or reliability of the information that has been provided to us. If you require any advice or information about the drugs on this page, a medical condition or treatment advice, you should always speak to a health professional. Please note that not all products, including any referenced in this page, are shipped by our affiliated Canadian Pharmacy. We affiliate with other dispensaries that ship product to our customers from the following jurisdictions: Canada, Singapore, New Zealand, Turkey, Mauritius, India, and United Kingdom. The items in your order maybe shipped from any of the above jurisdictions. The products are sourced from various countries as well as those listed above. Rest assured, we only affiliate with our authorized dispensaries that procure product through reliable sources.

Back to Main Drug Information Page